Guardant Health Inc. (GH) Reports Q3 Loss of $1.94, Revenues Beat; Offers FY18 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Guardant Health Reports Third Quarter 2018 Financial Results
November 19, 2018 4:05 PM ESTRevenue growth of 95% over prior year period
REDWOOD CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the third quarter ended September 30, 2018.
Recent Highlights
Revenues of $21.7 million for the third quarter of 2018, representing a 95% increase over the third quarter of 2017Reported 7,027 tests to clinical customers and 2,505 tests to biopharmaceutical customers in... More